Financial Performance - In 2024, the company achieved a revenue of CNY 21,609,592,228.45, representing a year-on-year growth of 42.95% [2] - The net profit attributable to shareholders was CNY 5,868,545,988.62, with a year-on-year increase of 117.01% [2] - In Q1 2025, the revenue reached CNY 5,439,577,817.97, showing a growth of 20.91% [2] - The net profit attributable to shareholders for Q1 2025 was CNY 1,879,910,462.58, reflecting a growth of 116.18% [2] Project Updates - The solid methionine project (70,000 tons) is still in the approval and construction phase [3] - The energy-saving review for the methionine project has not passed, but it does not affect the existing production and sales [3] - The liquid methionine project in partnership with Sinopec is currently in the trial production preparation stage [3] - The company has new material product plans in Zhejiang, Shandong, and Tianjin [3] Strategic Initiatives - The company is focused on the fine chemical industry, leveraging "Chemistry+" and "Biology+" as core technology platforms [4] - Future growth drivers include integrated, series, and collaborative development strategies, emphasizing innovation and the development of functional chemicals [4] - The company plans to continue its ESG initiatives, implementing sustainable development strategies and focusing on creating more value for society [4] - A share buyback plan of CNY 300 million to 600 million is set to enhance shareholder returns and boost market confidence [3]

Group 1 - The company reported Q1 2025 revenue of 5.44 billion yuan, a year-on-year increase of 20.9% and a quarter-on-quarter decrease of 6.66% [1] - The net profit attributable to the parent company reached 1.88 billion yuan, a year-on-year increase of 116.2% and a slight quarter-on-quarter increase, achieving a new record high [1] - The significant growth in performance is primarily attributed to the rise in prices of Vitamin E (VE) and methionine, with expectations for sustained high prices due to improved supply and demand dynamics [1][3] Group 2 - The average prices for VA/VE/VC/methionine in Q1 were 112.3/136.4/28.3/20.9 yuan/kg, representing year-on-year increases of 37.4%/109.9%/15.6%/-4.2% [2] - The company maintained a stable operation with a period expense ratio of 7%, which has been decreasing both year-on-year and quarter-on-quarter [2] - The gross profit margin was 46.7%, an increase of 11.7 percentage points year-on-year, while the net profit margin was 34.7%, an increase of 13.3 percentage points year-on-year [2] Group 3 - The supply-demand improvement in the methionine and VE markets is expected to support high price levels, with DSM planning to exit the vitamin market and leading methionine producers reducing production [3] - Recent price increases for methionine and VE are anticipated to positively impact the company's performance, with each 1 yuan/kg increase in price expected to add approximately 280 million yuan and 45 million yuan to profits, respectively [3] - The new materials business is experiencing rapid growth, with investments in various projects expected to accelerate future growth [3] Group 4 - The company forecasts net profits attributable to the parent company of 7.87 billion, 9.38 billion, and 9.76 billion yuan for 2025-2027, with corresponding EPS of 2.56, 3.05, and 3.18 yuan [4] - The current price corresponds to a PE ratio of 8.7, 7.3, and 7.0 for the respective years, maintaining a "buy" rating [4]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company achieved a revenue of 5.44 billion yuan in Q1 2025, representing a year-on-year increase of 20.9% and a quarter-on-quarter decrease of 6.66%. The net profit attributable to the parent company reached 1.88 billion yuan, a year-on-year increase of 116.2% and a slight quarter-on-quarter increase, marking a new high in profitability. The significant growth in performance is primarily attributed to the price increases of Vitamin E (VE) and methionine [1][2] - The supply-demand dynamics for VE and methionine are improving, with prices expected to remain high due to the reduction in production capacity by overseas leaders. The recent price adjustments by major companies indicate a positive trend for future profitability [3][4] Summary by Sections Financial Performance - In Q1 2025, the average prices for VA/VE/VC/methionine were 112.3/136.4/28.3/20.9 yuan/kg, with year-on-year changes of 37.4%/109.9%/15.6%/-4.2% and quarter-on-quarter changes of -33.3%/-3.0%/-2.8%/+4.8%. The net profit margin was 34.7%, up 13.3 percentage points year-on-year and 2.3 percentage points quarter-on-quarter. Operating cash flow reached 1.596 billion yuan, a year-on-year increase of 2.32 times [2][3] Market Outlook - The report anticipates continued price increases for methionine and VE, driven by supply constraints from major producers. The current price of methionine is 22.1 yuan/kg, up 12.5% year-on-year. Each 1 yuan/kg increase in methionine and VE is expected to enhance the company's performance by 280 million yuan and 45 million yuan, respectively [3][4] Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are 7.867 billion, 9.383 billion, and 9.761 billion yuan, with corresponding EPS of 2.56, 3.05, and 3.18 yuan. The current price corresponds to a PE ratio of 8.7, 7.3, and 7.0 for the respective years [4]

PPPPAAAARRRRTTTT 1111 关税落地，料A股回暖 关税"风暴"落地后，预计A股回暖、港股休整、美股修复。 4月初关税"风暴"即将落地，中国可能受影响最大，但准备也最充分；控供给、保需求，二季度国内政策发 力方向越发清晰。关税"风暴"落地后，预计A股回暖、港股休整、美股修复。从业绩层面来看，核心资产已 体现出极强的经营韧性，左侧布局的契机已经成熟；从流动性层面来看，活跃资金明显退潮，产业主题需 要催化及时间来蓄势。配置上，延续科技点火、供给侧发力和消费补短板的思路。 风险因素：中美科技、贸易、金融领域摩擦加剧；国内政策力度、实施效果及经济复苏不及预期；海内外 宏观流动性超预期收紧；俄乌、中东地区冲突进一步升级；我国房地产库存消化不及预期。 点击查看全文 外部扰动加大，聚焦三大主题 秦培景 刘易 王冠然 侯苏洋 卿施典 任恒毅 白弘伟 田鹏 王涛 王子昂 随着A股进入业绩披露期，以及外部扰动加大，市场整固的同时主题风格高低切换，前期市场关注度较高的 主题退潮，业绩、关税等因素成为新催化，建议关注业绩超预期主题、化工原料涨价主题、中美博弈主 题。我们延续从3月份以来的配置观点，建议继续关注业绩确定性 ...